KO Client Finding Hope for Frizzle and Apertura Gene Therapy Announce License Agreement

KO client Finding Hope for Frizzle (FRRS1L), a parent-led nonprofit organization working to develop a lifesaving treatment for FRRS1L patients, and Apertura Gene Therapy recently announced a license agreement to develop a gene therapy using Apertura’s TfR1 CapX technology.

“Although FRRS1L is a horrible and devastating disease robbing children of all motor ability by age two, we believe FRRS1L is a great candidate for treatment with gene therapy using Apertura’s TfR1 CapX technology,” said Chrissy Green, Co-Founder and President of Finding Hope for Frizzle (FRRS1L). “FRRS1L mouse models have shown promising results when given AAV gene therapy in unpublished preclinical studies, which motivates us to work to advance this treatment as soon as possible with the goal of saving the lives of current and future patients. We believe our efforts will help move gene therapy forward for the treatment of neurological and rare diseases.”

KO partner Brad Schoenfeld and attorney John Shearer represent Finding Hope for Frizzle and assisted with the negotiation of the license agreement. Read more in the press release.